New Generation Expands In AstraZeneca's Vacated Campus
This article was originally published in Scrip
When AstraZeneca plc decided three years ago to relocate its R&D headquarters from its Alderley Park campus in the Northwest of England to be nearer the biotech action around Cambridge, a research park built to accommodate thousands of scientists suddenly faced the prospect of becoming a ghost town. However, for Dr Neil Murray, CEO of local firm Redx Pharma, the site represents a great opportunity.
You may also be interested in...
After a tough summer, the UK firm has exited insolvency with new management and programs in cancer and fibrosis, having decided to shut down its anti-infectives business.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.